{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-089234","form_type":"8-K","ticker":"CERS","cik":"0001020214","company_name":"CERUS CORP","filed_at":"2024-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.906346+00:00","generated_at":"2026-05-31T13:35:54.416191+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cerus Q2 product revenue up 16% to $45M; raises FY2024 guidance to $175-178M","bullets":["Q2 product revenue $45.1M (+16% YoY); total revenue $50.5M (+6% YoY).","GAAP net loss narrowed to $5.8M ($0.03/share) from $13.3M loss in Q2 2023.","Non-GAAP adjusted EBITDA turned positive at $0.8M (vs -$4.7M prior year).","Full-year product revenue guidance raised to $175-178M; IFC guidance unchanged at $8-10M.","Canadian Blood Services achieved 100% INTERCEPT platelet adoption."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-089234","json":"https://secwatch.observer/filing/0000950170-24-089234.json","markdown":"https://secwatch.observer/filing/0000950170-24-089234.md","text":"https://secwatch.observer/filing/0000950170-24-089234.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1020214/000095017024089234/0000950170-24-089234-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1020214/000095017024089234/cers-20240801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:35:54.416191+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}